Respiratory syncytial virus vaccine development

Current Opinion in Pediatrics

Volumn 12, Issue 3, 2000, Pages 257-262

  Kahn, Jeffrey S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERIMMUNE GLOBULIN; LIVE VACCINE; MONOCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ARTICLE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; MOTHER; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINE PRODUCTION;

ADULT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; PREGNANCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL VACCINES;

EID: 0034127310     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200006000-00015     Document Type: Article

References (51)

1. 1 Hall CB: Respiratory syncytial virus. In Textbook of Pediatric Infectious Diseases, edn 3, vol 2. Edited by Feigin RD, Cherry JD. Philadelphia: WB Saunders; 1992:1633-1656.
2. 2 Monto AS: Acute respiratory infection in children of developing countries: challenge of the 1990s. Rev Infect Dis 1989, 11:498-505.
3. 3 Heilman CA: Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990, 161:402-406.
4. 4 Henderson FW. Collier AM, Clyde WA Jr, Denny FW: Respiratory-syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979, 300:530-534.
5. 5 Groothuis JR, Gutierrez KM, Lauer BA: Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988, 82:199-203.
6. 6 Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, et al.: Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986, 315:77-81.
7. 7 MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA: Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982, 307:397-400.
8. 8 Heikkinen T, Thint M, Chonmaitree T: Prevalence of various respiratory viruses in the middle ear during acute otitis media [see comments]. N Engl J Med 1999, 340:260-264. Respiratory syncytial virus was the most prevalent virus identified from children with acute otitis media. Invasion of the middle ear by RSV was demonstrated. This study strongly suggests that RSV plays a major role in the pathogenesis of acute otitis media.
9. 9 Eskola J, Hovi T: Respiratory viruses in acute otitis media [editorial; comment]. N Engl J Med 1999, 340:312-314. This editorial comment discusses the results of numerous studies concerning the importance of respiratory viruses in otitis media. The conclusions are clear: prevention of respiratory viral infection will likely reduce the incidence of otitis media.
10. 10 Han LL, Alexander JP, Anderson LJ: Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999, 179:25-30. Respiratory syncytial virus is an important cause of respiratory tract disease among the elderly. The incidence and direct medical costs of RSV pneumonia among the elderly are substantial and warrant evaluation of an RSV vaccine in this population.
11. 11 Falsey AR: Respiratory syncytial virus infection in older persons. Vaccine 1998, 16:1775-1778.
12. 12 Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I, et al.: Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996, 22:778-782.
13. 13 Perlstein PH, Kotagal UR, Bolling C, Steele R, Schoettker PJ, Atherton HD, et al.: Evaluation of an evidence-based guideline for bronchiolitis. Pediatrics 1999, 104:1334-1341. The lack of effectiveness of bronchodilator therapy in RSV disease is emphasized. Evidence-based guidelines were successful in decreasing the rates of hospitalizations strictly for β2 agonist therapy.
14. 14 Rodriguez WJ: Management strategies for respiratory syncytial virus infections in infants. J Pediatr 1999, 135(2 part 2):45-50. This is a comprehensive review of the treatment modalities available for RSV disease. Management of hospitalized infants and children with RSV is predominantly supportive.
15. 15 American Academy of Pediatrics Committee on Infectious Diseases: Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections [see comments]. Pediatrics 1996, 97:137-140.
16. 16 Murphy BR, Hall SL, Kulkarni AB, Crowe JE, Jr., Collins PL, Connors M, et al.: An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 1994, 32:13-36.
17. 17 Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89:405-421.
18. 18 Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al.: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
19. 19 Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, et al.: Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986, 24:197-202.
20. 20 Kim HW, Leikin SL, Arrobio J, Brandt CD, Chanock RM, Parrott RH: Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976, 10:75-78.
21. 21 Graham BS: Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am J Respir Crit Care Med 1995, 152(4 part 2):S63-S66.
22. 22 Collins PL, McIntosh K, Chancock RM: Respiratory syncytial virus. In Fields Virology, edn 3, vol 1. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia: Lippincott-Raven Publishers; 1996:1313-1351.
23. 23 Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, et al.: Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985, 151:626-633.
24. 24 Anderson LJ, Hendry RM, Pierik LT, Tsou C, McIntosh K: Multicenter study of strains of respiratory syncytial virus. J Infect Dis 1991, 163:687-692.
25. 25 Hendry RM, Talis AL, Godfrey E, Anderson LJ, Fernie BF, McIntosh K: Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks. J Infect Dis 1986, 153:291-297.
26. 26 Hendry RM, Pierik LT, McIntosh K: Prevalence of respiratory syncytial virus subgroups over six consecutive outbreaks: 1981-1987. J Infect Dis 1989, 160:185-190.
27. 27 Walsh EE, McConnochie KM, Long CE, Hall CB: Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis 1997, 175:814-820.
28. 28 Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P: Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993, 167:191-195.
29. 29 Belshe RB, Anderson EL, Walsh EE: Immunogenicity of purified F glyco-protein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993, 168:1024-1029.
30. 30 Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, Lewin EB, Oren J, et al.: Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 1994, 13:792-798.
31. 31 Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA: Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998, 177:467-469. Although the numbers of children studied are small, the subunit vaccine was safe and immunogenic in children with bronchopulmonary dysplasia. All children were more than 12 months old and had evidence of an RSV infection before the start of the study.
32. 32 Piedra PA, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman DA, et al.: Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996, 15:23-31.
33. 33 Falsey AR, Walsh EE: Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997, 15:1130-1132.
34. 34 Siegrist CA, Plotnicky-Gilquin H, Cordova M, Berney M, Bonnefoy JY, Nguyen TN, et al.: Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J Infect Dis 1999, 179:1326-1333.
35. 35 Bastien N, Trudel M, Simard C: Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 1999, 17:832-836. This is an intriguing study of the use of mucosal immunity elicited by synthetic peptides. The results of this study in mice necessitate confirmation in humans.
36. 36 McIntosh K, Arbeter AM, Stahl MK, Orr IA, Hodes DS, Ellis EF: Attenuated respiratory syncytial virus vaccines in asthmatic children. Pediatr Res 1974, 8:689-696.
37. 37 Pringle CR, Filipiuk AH, Robinson BS, Watt PJ, Higgins P, Tyrrell DA: Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 1993, 11:473-478.
38. 38 Crowe JE Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR: Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995, 13:847-855.
39. 39 Karron RA, Wright PF, Crowe JE Jr, Clements-Mann ML, Thompson J, Makhene M, et al.: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997, 176:1428-1436.
40. 40 Wright PF, Karron RA, Crowe JE Jr, Belshe RB, Wittek AC, Whitehead SS, et al.: Evaluation of a live, attenuated respiratory syncytial virus vaccine candidate, cpts 248/404, in infancy [abstract]. Pediatr Res 1998, 43:161.
41. 41 Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, et al.: Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A 1997, 94:13961-13966.
42. 42 Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR: Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 1995, 92:11563-11567.
43. 43 Whitehead SS, Bukreyev A, Teng MN, Firestone CY, St Claire M, Elkins WR, et al.: Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 1999, 73:3438-3442.
44. 44 Bukreyev A, Whitehead SS, Bukreyeva N, Murphy BR, Collins PL: Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proc Natl Acad Sci U S A 1999, 96:2367-2372. This is an example of the capability of molecular biology. Expression of human genes in recombinant live attenuated vaccines may decrease virulence and increase immunogenicity.
45. 45 Newell KW, Duenas Lehmann A, LeBlanc DR, Garces Osorio N: The use of toxoid for the prevention of tetanus neonatorum: final report of a double-blind controlled field trial. Bull World Health Organ 1966, 35:863-871.
46. 46 Rahman M, Chen LC, Chakraborty J, Yunus M, Chowdhury AI, Sarder AM, et al.: Use of tetanus toxoid for the prevention of neonatal tetanus: 1: reduction of neonatal mortality by immunization of non-pregnant and pregnant women in rural Bangladesh. Bull World Health Organ 1982, 60:261-267.
47. 47 Lamprecht CL, Krause HE, Mufson MA: Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976, 134:211-217.
48. 48 The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants [see comments]. Pediatrics 1998, 102(3 part 1):531-537.
49. 49 Groothuis JR, Simoes EA, Hemming VG (Respiratory Syncytial Virus Immune Globulin Study Group): Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 1995, 95:463-467.
50. 50 Glezen WP, Alpers M: Maternal immunization. Clin Infect Dis 1999, 28:219-224. This is a concise review of the experiences and potential of maternal immunizations.
51. 51 Muiholland K, Suara RO, Siber G, Robertson D, Jaffar S, N'Jie J, et al.: Maternal immunization with Haemophilus influenzae type b polysaccharidetetanus protein conjugate vaccine in The Gambia. JAMA 1996, 275:1182-1188.